CDB 2914

OBJECTIVE To evaluate the efficacy and tolerability of the P receptor modulator CDB-2914 (Ulipristal, CDB). DESIGN Randomized… Expand

OBJECTIVE To test potential contraceptive mechanisms of the selective P receptor modulator CDB-2914 in the early luteal phase… Expand

OBJECTIVE: To evaluate whether 3-month administration of CDB-2914, a selective progesterone receptor modulator, reduces leiomyoma… Expand

Effects of progesterone receptor modulator CDB-2914 on the expression of the extracellular matrix (ECM) components were examined… Expand

BACKGROUND This study was conducted to evaluate the effects of graded concentrations (10(-8), 10(-7) and 10(-6) M) of… Expand

Background: All current major medications in treating endometriosis are effective in treating pain, most likely through… Expand

In determining the biological profiles of various antiprogestins, it is important to assess the hormonal and antihormonal… Expand

CDB-2914 (17 alpha-acetoxy-11 beta-[4-N,N-dimethylaminophenyl]-19-norpregna-4,9-diene-3,20-dione) is a 19-norprogesterone… Expand

To obtain selective antiprogestins, we have examined the in vitro antiprogestational/antiglucocorticoid properties of two novel… Expand

Previous studies in women have shown that the antiprogestin mifepristone delays or inhibits folliculogenesis. The purpose of this… Expand